Instruct patients to tell you if they get pregnant during treatment with mycophenolate
or within 6 weeks following discontinuation of treatment. If you learn that a patient
is pregnant.
- Report the pregnancy to the Mycophenolate Pregnancy Registry
- Encourage the patient to participate in the Mycophenolate Pregnancy Registry and
encourage patients to read the Mycophenolate Pregnancy Registry Frequently Asked
Questions for Patients on this website
When you report an eligible pregnancy to the Mycophenolate Pregnancy Registry, you
should provide your contact information. Also provide the Mycophenolate Pregnancy
Registry with information about the pregnancy and the patient’s contact information
so that she can be called for follow-up for this safety study. Provision of patient
contact and medical information to the Mycophenolate Pregnancy Registry is covered
by an HIPAA waiver.
When patients participate in the Mycophenolate Pregnancy Registry, they agree to
provide information about their pregnancy, including information about prenatal
drug exposure of any duration, maternal demography and history, and maternal and
fetal outcomes of pregnancies exposed to mycophenolate. Patients are encouraged
to participate in the Mycophenolate Pregnancy Registry as soon as their pregnancy
is known, preferably in the first trimester.